Cargando…

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients

Detalles Bibliográficos
Autores principales:	Zhang, Y, Owen, A, Egan, D, Sarfo, SF
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112964/ http://dx.doi.org/10.1186/1758-2652-13-S4-P183

Ejemplares similares

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection
por: Meng, Xianmin, et al.
Publicado: (2015)

Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin
por: Soeria-Atmadja, Sandra, et al.
Publicado: (2017)

Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV
por: Hui, KH, et al.
Publicado: (2016)

Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog
por: Shah, Manish B., et al.
Publicado: (2018)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
por: Metzger, Ingrid F., et al.
Publicado: (2019)

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
por: Gounden, Verena, et al.
Publicado: (2010)

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
por: Kudzi, William, et al.
Publicado: (2009)

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
por: Wang, Jing, et al.
Publicado: (2018)

Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity
por: Petros, Zelalem, et al.
Publicado: (2022)

Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone
por: Lu, Jinjun, et al.
Publicado: (2021)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele
por: Bordin Andriguetti, Natália, et al.
Publicado: (2021)

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
por: Dhoro, Milcah, et al.
Publicado: (2015)

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
por: Kitabi, Eliford Ngaimisi, et al.
Publicado: (2018)

Postmenstrual age and CYP2D6 polymorphisms determine urinary tramadol O-demethylation excretion in critically ill neonates and infants
por: Allegaert, K, et al.
Publicado: (2008)

Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz
por: Mardi, Parham, et al.
Publicado: (2022)

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
por: Mukonzo, Jackson K., et al.
Publicado: (2014)

CYP2B6*18 is associated with nevirpine hypersensitivity independently of HLA-C*04:01 in a Malawian HIV population
por: Carr, Daniel, et al.
Publicado: (2014)

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
por: Uttayamakul, Sumonmal, et al.
Publicado: (2010)

The clinical impact of CYP2C19 *2 and *3 polymorphism on Clopidogrel and cost analysis
por: Meman A, Al, et al.
Publicado: (2014)

Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line
por: Lee, Hye Ja, et al.
Publicado: (2011)

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana
por: Maseng, Monkgomotsi J, et al.
Publicado: (2021)

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
por: Thompson, AM, et al.
Publicado: (2010)

Hepatocellular response to acute kidney injury in the critically ill: serum induces CYP2D6 transcription
por: Lane, K, et al.
Publicado: (2015)

The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana
por: Maseng, Monkgomotsi J., et al.
Publicado: (2022)

Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis
por: Yoon, Ha Young, et al.
Publicado: (2020)

CYP2E1 and Parkinson’s disease in a MPTP-induced C57BL/6 mouse model
por: Basaran, Rahman, et al.
Publicado: (2013)

Hepatic drug metabolism by CYP2D6 in critically ill adults with AKI: effect of phenotype and AKI severity
por: Lane, K, et al.
Publicado: (2015)

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]
Publicado: (2021)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
por: Bojić, Mirza, et al.
Publicado: (2019)

CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study
por: Tadesse, Wondmagegn Tamiru, et al.
Publicado: (2022)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

CYP2D6 polymorphisms and their influence on risperidone treatment
por: Puangpetch, Apichaya, et al.
Publicado: (2016)

A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study
por: Damronglerd, Pansachee, et al.
Publicado: (2015)

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
por: Ota, Tomoko, et al.
Publicado: (2015)

The Evaluation of CYP2D6, CYP2C9, CYP2C19, and CYP2B6 Phenoconversion in Post-Mortem Casework: The Challenge of Forensic Toxicogenetics
por: Giorgetti, Arianna, et al.
Publicado: (2023)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
por: Lim, Sharoen Yu Ming, et al.
Publicado: (2022)

Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations
por: Ford, Graeme R., et al.
Publicado: (2022)

CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single-dose primaquine
por: Pett, Helmi, et al.
Publicado: (2014)

The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva
por: Jin, Ye, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_395b0hg85q7saufvp8pdmc683g